If you have been reading about bremelanotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
== Chemistry == BmKAEP is an inhibitory β-toxin and thus, a Na+ channel inhibitor. As with other mammal and insect toxins, BmKAEP is classified according to species and mechanism of action. BmKAEP is a 61-amino-acid protein derived from an 85-amino-acid precursor. The mature protein contains 8 cysteine residues that establish 4 disulfide bridges (4C-C). Despite its high homology with other depressant toxins, BmKAEP differs from them at residues 6, 7 and 39, which is thought to be important in determining its unique function. Its lysine residue, at position 51, also has a special feature: it interacts with mammalian Na+ channels.
While it is a common belief that breastfeeding causes breasts to sag, researchers have found that a woman's breasts sag due to four key factors: cigarette smoking, number of pregnancies, gravity, and weight loss or gain. Women sometimes wear bras because they mistakenly believe they prevent breasts from sagging as they get older. Physicians, lingerie retailers, teenagers, and adult women used to believe that bras were medically required to support breasts. In a 1952 article in Parents' Magazine, Frank H. Crowell erroneously reported that it was important for teen girls to begin wearing bras early. According to Crowell, this would prevent sagging breasts, stretched blood vessels, and poor circulation later on. This belief was based on the false idea that breasts cannot anatomically support themselves. Sports bras are sometimes used for cardiovascular exercise, sports bras are designed to secure the breasts closely to the body to prevent movement during high-motion activity such as running. Studies have indicated sports bras which are overly tight may restrict respiratory function.
MDMA, also known as 3,4-methylenedioxy-N-methylamphetamine or as 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine, is a chemical compound of the phenethylamine, amphetamine, and methylenedioxyphenethylamine (MDxx) families. It is a derivative of various related compounds including phenethylamine, amphetamine, methamphetamine, homopiperonylamine (MDPEA), and 3,4-methylenedioxyamphetamine (MDA). MDMA is a racemic mixture of two enantiomers, (R)-MDMA and (S)-MDMA.
Sozusagen Paris, Munich 2016: Hanser. Einbruch der Wirklichkeit: Auf dem Flüchtlingstreck durch Europa, Munich 2016: C. H. Beck. Entlang den Gräben: Eine Reise durch das östliche Europa bis nach Isfahan, Munich 2018: C. H. Beck. Morgen ist da: Reden, Munich 2019: C. H. Beck. Jeder soll von da, wo er ist, einen Schritt näher kommen: Fragen nach Gott, Munich 2022: Hanser. Was jetzt möglich ist: 33 politische Situationen, Munich 2022: C.H. Beck. ISBN 978-3-406-79023-2. Das Alphabet bis S. Roman, Munich 2023: Hanser. ISBN 978-3-446-27745-8. In die andere Richtung jetzt. Eine Reise durch Ostafrika, Munich 2024: C.H. Beck, ISBN 978-3-406-81969-8. with Mehrdad Zaeri (illustration): Zu Hause ist es am schönsten, sagte die linke Hand und hielt sich an der Heizung fest, Berlin 2025: Hanser, ISBN 978-3-446-28260-5. Wenn sich unsere Herzen gleich öffnen. Über Politik und Liebe, Munich 2025: C.H. Beck, ISBN 978-3-406-83887-3. Sommer 24. Roman. Hanser, Berlin 2026, ISBN 978-3-446-28576-7. Köln. E Jeföhl. C.H. Beck, München 2026, ISBN 978-3-406-85095-0.
== History == The historical events leading to the proposal of the Good Laboratory Practice (GLP) regulations are crucial for understanding why these regulations are important to improve the quality and integrity of chemical safety data. They were developed in response to concerns about the reliability of toxicity data from industry. The GLP regulations aim to standardize procedures and practices to ensure accurate, reliable, and traceable safety data. GLP was first introduced in New Zealand and Denmark in 1972, but only as quality standards for re-agents and lab materials (first created in Australia due to being isolated from western labs by the Japanese blockade of WW2); the US FDA heard about them from NZ at an international conference just as the below IBT scandal broke). During the 1960s and 1970s, a growing concern for environmental issues and health impacts of chemicals was one factor in increased federal regulation, particularly in the chemical and pharmaceutical sectors, leading to more stringent product testing requirements and the development of inspection programs targeting laboratories conducting animal research in developed countries. These initiatives, initiated in the US by the Office of New Drugs and the Office of Marketed Drugs in 1969 and later expanded with the Office of Compliance, included inspections of facilities with questionable study validity or misconduct tips, revealing significant quality control issues and deficiencies in animal toxicological testing standards and data reporting.
Sources: en.wikipedia.org
The scale uses a rating of zero to three to rate physical dependence, psychological dependence, and pleasure to create a mean score for dependence. Selected results can be seen in the chart below. Heroin and morphine both scored highest, at 3.0.
Gallium (68Ga) gozetotide or Gallium (68Ga) PSMA-11, is a radiopharmaceutical made of 68Ga conjugated to a inhibitor of the enzyme prostate-specific membrane antigen (PSMA) known as Glu-Urea-Lys(Ahx)-HBED-CC. It is used for imaging prostate cancer by positron emission tomography (PET). The PSMA inhibitor specifically directs the radiolabeled imaging agent towards the prostate cancerous lesions in men. The most common side effects with gallium (68Ga)-radiolabelled gozetotide are tiredness, nausea (feeling sick), constipation and vomiting. Gallium (68Ga) gozetotide was approved for medical use in the United States in December 2021, and in the European Union in December 2022. It is the first drug approved by the US Food and Drug Administration (FDA) as a PET imaging agent of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
In humans, fatty acids are formed from carbohydrates predominantly in the liver and adipose tissue, as well as in the mammary glands during lactation. The pyruvate produced by glycolysis is an important intermediary in the conversion of carbohydrates into fatty acids and cholesterol. This occurs via the conversion of pyruvate into acetyl-CoA in the mitochondrion. However, this acetyl-CoA needs to be transported into cytosol where the synthesis of fatty acids and cholesterol occurs. This cannot occur directly. To obtain cytosolic acetyl-CoA, citrate (produced by the condensation of acetyl-CoA with oxaloacetate) is removed from the citric acid cycle and carried across the inner mitochondrial membrane into the cytosol. There it is cleaved by ATP citrate lyase into acetyl-CoA and oxaloacetate. The oxaloacetate is returned to mitochondrion as malate (and then converted back into oxaloacetate to transfer more acetyl-CoA out of the mitochondrion). The cytosolic acetyl-CoA is carboxylated by acetyl-CoA carboxylase into malonyl-CoA, the first committed step in the synthesis of fatty acids.
One of the most common erroneous explanations of aerodynamic lift asserts that the air must traverse the upper and lower surfaces of a wing in the same amount of time. This implies that since the upper surface presents a longer path the air must be moving over the top of the wing faster than over the bottom. Bernoulli's principle is then cited to conclude that the pressure on top of the wing must be lower than on the bottom. This explanation is incorrect because there is no physical principle that requires equal transit time around solid bodies. Theory predicts – and experiments confirm – that for a body experiencing lift the air traverses the top surface of in a shorter time than it traverses the bottom surface. While the equal-time explanation is false, it is not the Bernoulli principle that is false, because this principle is well established; Bernoulli's equation is used correctly in common mathematical treatments of aerodynamic lift.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.